Axin-2/BCL2 axis regulates apoptosis upon targeting TAM kinase receptors in leukemia
This study demonstrates that targeting TAM kinase receptors in leukemia induces mitochondrial apoptosis via the Axin-2/BCL2 axis, suggesting that modulating this pathway could overcome therapy resistance and relapse.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Blood cancer, or leukemia, is a condition where the body produces too many immature white blood cells. These abnormal cells crowd out the healthy ones, leaving the body unable to fight infection or carry oxygen. For decades, doctors have tried to stop this growth by targeting the specific engines that drive these cells to multiply. One such engine is a group of proteins on the cell surface called TAM receptors. When these receptors are stuck in the "on" position, they tell the cancer cell to survive and ignore the body's natural signals to die. While drugs that block these receptors show promise, they do not work equally well for every type of leukemia. Some patients respond quickly, while others seem immune to the treatment, leading to relapse. The central mystery has been why blocking the same switch produces such different results in different patients.
A team of researchers set out to solve this puzzle by looking at what happens inside the cell after the TAM receptors are blocked. They focused on a specific type of cell death called apoptosis, which is the body's built-in mechanism for destroying damaged cells. In a healthy system, when a cell is sick, it triggers a chain reaction that leads to its own destruction. In leukemia, this mechanism is often broken. The researchers tested four different leukemia cell lines in the lab: two representing acute myeloid leukemia, one representing chronic myeloid leukemia, and one representing a type of acute lymphocytic leukemia. They treated these cells with drugs designed to block the TAM receptors and observed how the cells reacted.
The results revealed a stark divide. The cells representing acute myeloid leukemia stopped growing and began to die when the receptors were blocked. In contrast, the cells representing the other types of leukemia barely reacted, continuing to grow despite the treatment. To understand why, the scientists looked at the molecular signals inside the cells. They found that the key difference lay in a specific pair of proteins that act as a switch for cell death. One protein, called Axin-2, acts as a signal to start the dying process. The other, called BCL2, acts as a shield that protects the cell from dying. In the cells that responded well to the drug, blocking the TAM receptor caused the levels of the death signal to rise while the protective shield dropped. This combination allowed the cell to self-destruct.
However, in the cells that resisted the treatment, the opposite happened. Even though the TAM receptors were blocked, the protective shield remained high, and the death signal stayed low. The researchers discovered that this resistance was not just about the receptors themselves, but about how the cell's internal wiring interpreted the blockage. In the resistant cells, the protective protein BCL2 was so dominant that it prevented the cell from dying, even when other signals tried to trigger it. In one specific case, the researchers observed a different outcome where the cell stopped growing but did not die immediately. This happened because a third protein, which usually encourages growth, was present in high amounts but was being held in check by the protective shield, causing the cell to pause rather than perish.
The study suggests that the success of blocking TAM receptors depends entirely on the balance between these two opposing proteins. If the balance tips toward the death signal, the cancer cell dies. If the balance tips toward the protection, the cancer cell survives and continues to grow. This finding explains why some patients might not respond to current therapies; their cancer cells are wired to keep the protective shield up, regardless of the external drug. The researchers propose that to overcome this resistance, future treatments might need to target both the TAM receptors and this specific balance of proteins simultaneously. By forcing the protective shield down while the death signal is up, it may be possible to make even the most stubborn cancer cells succumb to the body's natural cleanup process. This work does not offer an immediate cure, but it provides a clear map of the molecular landscape, showing exactly where the treatment fails and where a new strategy could succeed.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.